The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

July 20, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Relapsed or Resistant Acute Leukaemias
Interventions
DRUG

LBS-007

Open Label.

Trial Locations (14)

6009

NOT_YET_RECRUITING

Q Medical Conselling, Perth

21287

NOT_YET_RECRUITING

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

27599

RECRUITING

UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill

33612

NOT_YET_RECRUITING

Moffitt Cancer Center, Tampa

60611

NOT_YET_RECRUITING

Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago

66205

RECRUITING

The University of Kansas Hospital, Fairway

Unknown

ACTIVE_NOT_RECRUITING

Wollongong Private Hospital, Wollongong

ACTIVE_NOT_RECRUITING

Pindara Private Hospital, Benowa

RECRUITING

The Royal Adelaide Hospital, Adelaide

RECRUITING

The Alfred Hospital, Melbourne

ACTIVE_NOT_RECRUITING

Hollywood Private Hospital, Nedlands

NOT_YET_RECRUITING

China Medical University Hospital, Taichung

NOT_YET_RECRUITING

National Cheng Kung University Hospital, Tainan City

NOT_YET_RECRUITING

National Taiwan University Hospital, Taipei

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Lin BioScience Pty Ltd

UNKNOWN

lead

Lin BioScience, Inc

INDUSTRY